These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, Oppenheimer analysts assumed coverage of Abeona Therapeutics stock (NASDAQ: NASDAQ:ABEO) with an Outperform rating and maintained a price target of $19. The $307 million market cap company, currently trading at $6.47, has analyst targets ranging from $11 to $27.50, reflecting strong consensus optimism. The analysts highlighted Abeona’s strong early momentum following the approval of ZEVASKYN in April.
The company has activated its first Qualified Treatment Center ahead of schedule, with the initial patient treatment anticipated in the third quarter of 2025. With a healthy current ratio of 4.9, Abeona has reported high levels of interest from patients, caregivers, and physicians, as evidenced by nationwide inquiries received by Abeona Assist and significant attention at the recent SID conference.
Progress on the payer front has also been noted, with agreements in place with Anton Rx and a major medical collective that serves approximately 100 million commercially insured individuals. This development supports the company’s positive outlook on ZEVASKYN’s commercial trajectory.
The Oppenheimer analysts’ report reflects confidence in the early launch progress of ZEVASKYN and its potential in the market. The coverage assumption and rating underscore the firm’s positive outlook on Abeona Therapeutics’ future performance.
In other recent news, Abeona Therapeutics reported a notable performance in its first-quarter 2025 earnings, achieving a smaller-than-expected loss per share. The company reported an earnings per share (EPS) of -$0.24, surpassing analyst forecasts of -$0.37. This positive outcome, along with FDA approval for its new therapy, ZivaSkin, marks significant progress for the company. Additionally, Abeona Therapeutics has strengthened its financial position by selling a priority review voucher, resulting in $152 million in net proceeds. This capital is expected to support the company’s operations for over two years, aligning with its goal of reaching profitability by early 2026.
Furthermore, the company has activated its first Zevaskyn Qualified Treatment Center, with the first patient treatment scheduled for August 2025. Approximately 30 patients and caregivers have shown interest by enrolling in the Abeona Assist program, which could impact revenue projections positively. On the analyst front, Stifel adjusted its price target for Abeona Therapeutics to $20, while maintaining a Buy rating, citing recent developments that could influence the company’s revenue in the second half of 2025. The company has also made strides in securing value-based agreements with several commercial payers, enhancing the accessibility of Zevaskyn to a broader patient base.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.